By InvitationPhase 2/3

Effects of Ketone Supplementation on Acute Alcohol Withdrawal

United States50 participantsStarted 2024-03-11

Plain-language summary

The goal of this study is to study the effects of the ketone supplement Kenetik compared to placebo (an inactive beverage) on alcohol withdrawal symptoms during the 5 days of clinical alcohol withdrawal management treatment at the Caron Treatment Center.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Meets current DSM-5 criteria for AUD and admitted for alcohol withdrawal management treatment at Caron Treatment Center
✓. Willingness to provide signed, informed consent and commit to completing the procedures in the study

Exclusion criteria

✕. Current, gastrointestinal (GI), liver or other clinically significant physical disease that may interfere with the intake of the Ketone Supplement based on medical history, and evaluation of the Study Physician.
✕. Currently pregnant or lactating, based on urine pregnancy test and clinical exam.
✕. Current significant withdrawal from other substances, including benzodiazepines, opioids that require medication management for withdrawal and may interfere with study results/withdrawal management plan.
✕. Judged by the principal investigator, Study Physician, or their designee to be an unsuitable candidate for the study.

What they're measuring

Effects of ketone supplement Kenetik, three times daily (TID), versus placebo, on the need for benzodiazepines (daily use in mg).

Timeframe: 5 days

Trial details

NCT IDNCT06173973

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Alcohol Use Disorder trials